Kull Circius Pharma (Charcoal, Activated)

• Kull Circius Pharma (activated charcoal) is used in the gastrointestinal adsorbent class to manage toxin exposure and related conditions.
• Acute poisoning: Reduces systemic absorption of ingested poisons, supporting rapid gastrointestinal decontamination and limiting toxicity.
• Drug overdose: Binds excess oral medications in the gastrointestinal lumen, decreasing further absorption and aiding clinical management of overdose.
• Digestive disturbances: Adsorbs excess gas and luminal toxins, helping to relieve bloating, flatulence and mild abdominal discomfort.

• Activated charcoal consists of porous carbon particles with a large surface area that bind a wide range of organic and inorganic substances through physical adsorption and electrostatic interactions. When administered orally, the particles remain in the gastrointestinal tract, where they sequester toxins, drugs, gases and metabolic by‑products, preventing their passage across the mucosal barrier and thereby reducing systemic exposure overall.

Activated charcoal is generally well tolerated, but oral administration can be associated with several adverse reactions.

Common Side Effects

• Nausea: Mild nausea may develop within minutes of taking the product.
• Vomiting: Occasional vomiting can occur, particularly when administered without food.
• Constipation: Transient constipation may result from the bulk‑forming charcoal particles.
• Black stools: Feces often turn dark or black due to the pigment of charcoal.

Serious or Rare Side Effects

• Aspiration: Inhalation of vomited charcoal may cause pulmonary aspiration and respiratory compromise.
• Bowel obstruction: Rare mechanical obstruction can arise in patients with existing gastrointestinal disease.
• Electrolyte imbalance: Prolonged constipation may lead to disturbances in electrolytes such as potassium.
• Hypersensitivity: Uncommon allergic reactions, including rash, urticaria or angioedema, have been reported.

When using activated charcoal, certain precautions should be observed to ensure safety and effectiveness.

• Indication verification: Confirm that the patient’s condition requires gastrointestinal decontamination before administration.
• Timing of dose: Administer as soon as possible after ingestion of the toxin for optimal adsorption.
• Concomitant medications: Separate administration of other oral drugs by at least 2 hours to avoid reduced efficacy.
• Patient monitoring: Observe for signs of vomiting, aspiration or worsening gastrointestinal obstruction.
• Contraindications: Avoid use in patients with known gastrointestinal perforation or obstruction.
• Store at ambient temperature: Keep the product below 25 °C in the original packaging, protected from moisture and direct sunlight.

Activated charcoal can affect the absorption of several other substances, leading to clinically relevant drug interactions.

Major Interactions (Avoid)

• Oral anticoagulants: Charcoal may bind warfarin or direct oral anticoagulants, diminishing their therapeutic effect.
• Anticonvulsants: Reduced absorption of phenytoin or carbamazepine can compromise seizure control and increase seizure risk.
• Antidepressants: Binding of tricyclic antidepressants may lower plasma concentrations, reducing efficacy.

Moderate Interactions (Monitor Closely)

• Antacids: Simultaneous use may alter charcoal’s adsorption capacity and affect antacid efficacy, requiring monitoring.
• Oral antibiotics: Co‑administration may decrease antibiotic bioavailability; monitor infection response and consider timing adjustments.
• Thyroid hormones: Levothyroxine absorption can be reduced; consider separating doses by at least 2 hours.